Last updated: 11/03/2018 22:42:41

Efficacy study of protein supplementation in attenuating the decline in performance after strenuous concurrent exercise

GSK study ID
204676
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A Study to Evaluate the Effects of Protein Supplementation in Attenuating the Decline in Performance Following Strenuous Concurrent Exercise
Trial description: This study is designed to investigate whether protein supplementation can improve recovery of muscle function following a strenuous combination of both endurance and resistance exercise. It will specifically investigate the effect of protein supplementation on the recovery of strength, power and endurance exercise performance, along with measures of damage and inflammation of the muscle.
Primary purpose:
Supportive Care
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:

Isometric Maximal Voluntary Contraction (MVC) Assessment

Timeframe: 96 hours (h)

Counter Movement Jump (CMJ) Assessment

Timeframe: 96 h

16.1 Kilometer (km) Cycling Time Trial (TT) Assessment

Timeframe: 96 h

Secondary outcomes:

Serum Creatine Kinase Analysis

Timeframe: 96 h

Serum C-Reactive Protein Analysis

Timeframe: 96 h

Perceived Muscle Soreness Assessment

Timeframe: 96 h

Interventions:
  • Dietary supplement: Test product
  • Dietary supplement: Reference product 1
  • Dietary supplement: Reference product 2
  • Enrollment:
    24
    Primary completion date:
    Not applicable
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Not applicable
    Medical condition
    Sports Nutritional Sciences
    Product
    Not applicable
    Collaborators
    Not applicable
    Study date(s)
    June 2015 to February 2016
    Type
    Interventional
    Phase
    Not applicable

    Participation criteria

    Sex
    Male
    Age
    18 - 35 years
    Accepts healthy volunteers
    Yes
    • Understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary informed consent form and has received signed and dated copy of the informed consent form
    • Male participants; age between 18 to 35 years, inclusive
    • Currently taking any nutritional supplements, polyphenols or beta-blockers, Non-steroidal anti-inflammatory drugs (NSAIDs), recreational drugs
    • Known or suspected intolerance or hypersensitivity to the study material or any of their stated ingredients

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Brentford, United Kingdom, TW8 9 DA
    Status
    Study Complete

    Study documents

    Scientific result summary
    Available language(s): English

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    Study complete
    Actual primary completion date
    Not applicable
    Actual study completion date
    2016-12-02

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Additional information
    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website